[Multicenter randomized controlled clinical study for the operative treatment of malignant ovarian germ cell tumors]
- PMID: 23849941
[Multicenter randomized controlled clinical study for the operative treatment of malignant ovarian germ cell tumors]
Abstract
Objective: To investigate the operative treatment for first-treated patients with malignant ovarian germ cell tumors who need preservation of fertility.
Methods: The clinical data of 105 patients who were treated with fertility-sparing surgery in 11 hospitals from 1992 to 2010 were collected to evaluate the outcomes of different primary surgical operative procedures. All 105 cases were performed the surgeries that preserved fertility and divided into three groups according to the surgical approaches, comprehensive staging surgery group: 47 cases (44.8%) received comprehensive staging surgeries that including the ipsilateral oophorectomy + omentectomy + retropertoneal lymph node dissection ± appendectomy + multiple biopsies;oophorectomy group:45 cases (42.9%)received ipsilateral oophorectomy ± biopsy of contralateral ovary ± omentectomy;tumor resection group:13 cases (12.4%) received enucleation of the mass with preservation of the ovary. Differences were compared among the three groups of patients in the surgery-related indicators, complications, fertility and prognosis.
Results: (1) Surgery-related indicators:the average blood loss of the comprehensive staging surgery group, the oophorectomy group and the tumor resection group were 496, 104 and 253 ml, the mean operation time were 176, 114 and 122 minutes, respectively, and there were significant differences among three groups (P = 0.011, P = 0.000). (2) Complication:the surgical complication rates of the three groups were 17% (8/47), 0 and 1/13, with significant differences (P = 0.015). (3) Reproductive function status: the pregnancy rate and birth rate of the three groups were no significant differences (9/19 vs. 7/19 vs. 2/3, P = 0.515; 8/19 vs. 5/19 vs. 2/3, P = 0.636). (4) PROGNOSIS: the recurrence rate of the three groups were significant differences [13% (6/47) vs. 0 vs. 2/13, P = 0.013], but the death rate with no significant differences [6% (3/47) vs. 0 vs. 0, P = 0.129]; The five-year survival rate of three different groups were 89%, 100% and 100% (P > 0.05), while disease free survival rate were 85%, 100% and 83% (P < 0.05), respectively.
Conclusions: Compared with comprehensive staging surgery, oophorectomy group have higher surgical security and satisfactory prognosis, considerable pregnancy rates and birth rate. The tumor resection security may be reliable, but the prognosis is poor.
Similar articles
-
The significance of comprehensive staging surgery in malignant ovarian germ cell tumors.Gynecol Oncol. 2013 Dec;131(3):551-4. doi: 10.1016/j.ygyno.2013.08.016. Epub 2013 Sep 2. Gynecol Oncol. 2013. PMID: 24007946
-
Fertility-Sparing Surgery Should Be the Standard Treatment in Patients with Malignant Ovarian Germ Cell Tumors.J Adolesc Young Adult Oncol. 2017 Jun;6(2):270-276. doi: 10.1089/jayao.2016.0086. Epub 2017 Jan 13. J Adolesc Young Adult Oncol. 2017. PMID: 28085535
-
[Prognostic factors analysis in patients with ovarian malignant germ cell tumor treated with fertility-preserving surgery].Zhonghua Fu Chan Ke Za Zhi. 2012 Dec;47(12):898-904. Zhonghua Fu Chan Ke Za Zhi. 2012. PMID: 23324188 Chinese.
-
[Results of fertility preserving operations in malignant ovarian tumors].Zentralbl Gynakol. 1996;118(6):317-21. Zentralbl Gynakol. 1996. PMID: 8768006 Review. German.
-
Oncologic and reproductive outcome after fertility-saving surgery in ovarian cancer.Eur J Gynaecol Oncol. 2003;24(3-4):223-32. Eur J Gynaecol Oncol. 2003. PMID: 12807228 Review.
Cited by
-
Clinicopathological factors and prognosis analysis of 39 cases of non-gestational ovarian choriocarcinoma.Arch Gynecol Obstet. 2020 Apr;301(4):901-912. doi: 10.1007/s00404-020-05502-9. Epub 2020 Mar 17. Arch Gynecol Obstet. 2020. PMID: 32185550 Review.
-
Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.Cochrane Database Syst Rev. 2022 Aug 30;8(8):CD007697. doi: 10.1002/14651858.CD007697.pub3. Cochrane Database Syst Rev. 2022. PMID: 36041232 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical